IISc spinout Venomics AI secures $2.7m for venom-based drug discovery

Venomics AI, a spinout from the Indian Institute of Science, has secured $2.7 million in pre-seed funding to advance its novel approach to drug discovery using animal venom toxins. The capital injection will enable the company to expand its Venom Atlas, a comprehensive molecular database of venom-derived compounds with potential therapeutic applications.

The startup will deploy the funds across three strategic areas: enhancing its Venom Atlas repository, strengthening artificial intelligence-powered drug discovery capabilities, and scaling laboratory screening operations. By systematizing venom research through computational tools, Venomics AI aims to identify promising drug candidates more efficiently than traditional methods.

Venom-based drug discovery represents an emerging frontier in pharmaceutical research. Natural toxins from snakes, spiders, scorpions, and marine organisms contain bioactive compounds that have evolved to target specific biological pathways, making them valuable starting points for therapeutic development. Several venom-derived treatments have already reached clinical use, particularly in pain management and cardiovascular disease.

The company's AI-led approach combines machine learning analysis of venom peptides with experimental validation to accelerate the identification of viable drug candidates. This methodology reduces development timelines and potentially lowers costs associated with conventional drug discovery pipelines.

Venomics AI joins a growing ecosystem of Indian biotech startups leveraging cutting-edge technology for pharmaceutical innovation. The funding underscores investor confidence in India's capacity to develop high-impact healthcare solutions addressing global therapeutic needs.